Do analysts prefer RFL or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Does the media refer more to RFL or CLRB?

In the previous week, Cellectar Biosciences had 1 more articles in the media than Rafael. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Rafael. Rafael's average media sentiment score of 0.67 beat Cellectar Biosciences' score of -0.87 indicating that Rafael is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Which has preferable earnings and valuation, ALDX or CLRB?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is ALDX or CLRB more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Cellectar Biosciences N/A -185.35% -115.42%

Does the media refer more to ALDX or CLRB?

In the previous week, Aldeyra Therapeutics had 9 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Aldeyra Therapeutics and 2 mentions for Cellectar Biosciences. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Cellectar Biosciences' score of -0.87 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Which has preferable valuation & earnings, CGTX or CLRB?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is CGTX or CLRB more profitable?

Cognition Therapeutics' return on equity of -50.17% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Cellectar Biosciences N/A -185.35% -115.42%

Does the media favor CGTX or CLRB?

In the previous week, Cellectar Biosciences had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Cellectar Biosciences' score of -0.87 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Which has stronger valuation & earnings, PYPD or CLRB?

PolyPid is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is PYPD or CLRB more profitable?

Cellectar Biosciences' return on equity of -185.35% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Cellectar Biosciences N/A -185.35% -115.42%

Does the media prefer PYPD or CLRB?

In the previous week, PolyPid and PolyPid both had 2 articles in the media. PolyPid's average media sentiment score of 0.61 beat Cellectar Biosciences' score of -0.87 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Cellectar Biosciences (CLRB) Competitors

$2.52 -0.07 (-2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.51 -0.01 (-0.40%)

As of 04:12 PM Eastern

Compare

CLRB vs. RFL, FBIO, ALDX, CGTX, and PYPD

Should you buy Cellectar Biosciences stock or one of its competitors? Cellectar Biosciences's main competitors and comparable companies include Rafael (RFL), Fortress Biotech (FBIO), Aldeyra Therapeutics (ALDX), Cognition Therapeutics (CGTX), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cellectar Biosciences compare to Rafael?

Rafael (NYSE:RFL) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

11.3% of Rafael shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cellectar Biosciences had 1 more articles in the media than Rafael. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Rafael. Rafael's average media sentiment score of 0.67 beat Cellectar Biosciences' score of -0.87 indicating that Rafael is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Rafael has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Cellectar Biosciences has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$980K	115.62	-$30.52M	-$0.68	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Cellectar Biosciences has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Summary

Cellectar Biosciences beats Rafael on 10 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Cellectar Biosciences' score of -0.87 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Cellectar Biosciences	Negative

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 480.20%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 336.51%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Cellectar Biosciences' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Fortress Biotech has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.54	$6.82M	$2.64	1.11
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Summary

Fortress Biotech beats Cellectar Biosciences on 12 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Aldeyra Therapeutics' return on equity of -53.14% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Aldeyra Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 261.84%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Aldeyra Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 9 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Aldeyra Therapeutics and 2 mentions for Cellectar Biosciences. Aldeyra Therapeutics' average media sentiment score of 0.83 beat Cellectar Biosciences' score of -0.87 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Aldeyra Therapeutics beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Cellectar Biosciences had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.79 beat Cellectar Biosciences' score of -0.87 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Cognition Therapeutics' return on equity of -50.17% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 238.58%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Cognition Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Summary

Cognition Therapeutics beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cellectar Biosciences' return on equity of -185.35% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Cellectar Biosciences	N/A	-185.35%	-115.42%

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 127.12%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

PolyPid is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, PolyPid and PolyPid both had 2 articles in the media. PolyPid's average media sentiment score of 0.61 beat Cellectar Biosciences' score of -0.87 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Cellectar Biosciences beats PolyPid on 7 of the 12 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.81M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-0.66	780.42	271.39	24.10
Price / Sales	N/A	789.54	604.58	77.05
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	1.33	10.42	11.18	6.40
Net Income	-$21.79M	$2.79B	$3.46B	$348.28M
7 Day Performance	-1.56%	2.25%	1.98%	0.92%
1 Month Performance	4.56%	4.72%	7.32%	5.10%
1 Year Performance	-48.36%	7.07%	24.76%	16.16%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	2.7678 of 5 stars	$2.52 -2.7%	$11.00 +336.5%	-46.9%	$23.81M	N/A	N/A	10
RFL Rafael	0.4852 of 5 stars	$1.88 +0.3%	N/A	+37.9%	$97.55M	$980K	N/A	20	Gap Up
FBIO Fortress Biotech	1.6494 of 5 stars	$2.91 +3.2%	$17.00 +484.2%	+26.4%	$96.67M	$63.26M	1.10	170
ALDX Aldeyra Therapeutics	3.4189 of 5 stars	$1.55 -0.6%	$5.50 +254.8%	-73.8%	$93.51M	N/A	N/A	10
CGTX Cognition Therapeutics	2.7911 of 5 stars	$0.98 -3.7%	$3.33 +239.5%	-64.6%	$93.37M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. RFL, FBIO, ALDX, CGTX, and PYPD

How does Cellectar Biosciences compare to Rafael?

Summary

How does Cellectar Biosciences compare to Fortress Biotech?

Summary

How does Cellectar Biosciences compare to Aldeyra Therapeutics?

Summary

How does Cellectar Biosciences compare to Cognition Therapeutics?

Summary

How does Cellectar Biosciences compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. RFL, FBIO, ALDX, CGTX, and PYPD

How does Cellectar Biosciences compare to Rafael?

Do institutionals & insiders hold more shares of RFL or CLRB?

Does the media refer more to RFL or CLRB?

Do analysts prefer RFL or CLRB?

Which has more volatility & risk, RFL or CLRB?

Which has stronger earnings and valuation, RFL or CLRB?

Is RFL or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to Fortress Biotech?

Does the media prefer FBIO or CLRB?

Do analysts prefer FBIO or CLRB?

Do insiders and institutionals have more ownership in FBIO or CLRB?

Which has more volatility & risk, FBIO or CLRB?

Is FBIO or CLRB more profitable?

Which has stronger valuation & earnings, FBIO or CLRB?

Summary

How does Cellectar Biosciences compare to Aldeyra Therapeutics?

Do institutionals and insiders believe in ALDX or CLRB?

Which has preferable earnings and valuation, ALDX or CLRB?

Is ALDX or CLRB more profitable?

Do analysts recommend ALDX or CLRB?

Which has more risk and volatility, ALDX or CLRB?

Does the media refer more to ALDX or CLRB?

Summary

How does Cellectar Biosciences compare to Cognition Therapeutics?

Does the media favor CGTX or CLRB?

Is CGTX or CLRB more profitable?

Do analysts prefer CGTX or CLRB?

Do institutionals and insiders hold more shares of CGTX or CLRB?

Which has preferable valuation & earnings, CGTX or CLRB?

Which has more volatility & risk, CGTX or CLRB?

Summary

How does Cellectar Biosciences compare to PolyPid?

Do insiders & institutionals have more ownership in PYPD or CLRB?

Is PYPD or CLRB more profitable?

Do analysts rate PYPD or CLRB?

Which has stronger valuation & earnings, PYPD or CLRB?

Which has more risk & volatility, PYPD or CLRB?

Does the media prefer PYPD or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools